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GPCRThe chemokine receptor CXCR4 interacts with a single endogenous chemokine, CXCL12, and regulates a wide
variety of physiological and pathological processes including inﬂammation and metastasis development.
CXCR4 also binds the HIV-1 envelope glycoprotein, gp120, resulting in viral entry into host cells. Therefore,
CXCR4 and its ligands represent valuable drug targets. In this study, we investigated the inhibitory properties
of synthetic peptides derived from CXCR4 extracellular loops (ECL1-X4, ECL2-X4 and ECL3-X4) towards HIV-1
infection and CXCL12-mediated receptor activation. Among these peptides, ECL1-X4 displayed anti-HIV-1
activity against X4, R5/X4 and R5 viruses (IC50= 24 to 76 μM) in cell viability assaywithout impairing physiolog-
ical CXCR4–CXCL12 signalling. In contrast, ECL2-X4 only inhibited X4 and R5/X4 strains, interfering with HIV-
entry into cells. At the same time, ECL2-X4 strongly and speciﬁcally interacted with CXCL12, blocking its binding
to CXCR4 and its second receptor, CXCR7 (IC50 = 20 and 100 μM). Further analysis using mutated and truncated
peptides showed that ECL2 of CXCR4 forms multiple contacts with the gp120 protein and the N-terminus of
CXCL12. Chemokine neutralisation was mainly driven by four aspartates and the C-terminal residues of ECL2-
X4. These results demonstrate that ECL2 represents an important structural determinant in CXCR4 activation.
We identiﬁed the putative site for the binding of CXCL12 N-terminus and provided new structural elements to
explain the recognition of gp120 and dimeric CXCR4 ligands.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The chemokine receptor CXCR4 is a class A G-protein-coupled
receptor (GPCR) expressed at the surface of a large variety of cells
including T lymphocytes, monocytes, neutrophils, dendritic and
endothelial cells [1–3]. The interaction of CXCR4 with its unique
endogenous ligand, the chemokine CXCL12, also named SDF1α,
plays a crucial role in various processes such as hematopoietic stem
cell [4,5] and leukocyte trafﬁcking [6,7], vascular and neuronal
development as well as inﬂammation and immune-modulation
[5,7,8]. In addition to its physiological role, CXCR4 is involved in
several pathologies including inﬂammatory diseases, WHIM (Warts,
Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome,
cancer and HIV-1 infection [9–13]. CXCR4 and another chemokine
receptor, CCR5, act as co-receptors for the entry of HIV-1 into host
cells by interacting with the viral envelope protein gp120 after its
engagement with CD4 [11,14–21]. Viruses enter via CCR5 or CXCR4352 26 970 221.
gné).
s Edison 1A-B, L-1445 Strassen,
ights reserved.(termed “R5 viruses” and “X4 viruses”), or use both co-receptors
(termed “R5/X4” or dual tropic viruses). Viruses using CCR5 are
believed to be preferentially transmitted as they infect effectormemory
CD4+ T-cells as well as macrophages and dendritic cells, which are
abundant underneath the epithelial layer where infection occurs.
Viruses utilising CXCR4, preferentially infecting naïve CD4 T-cells, gen-
erally appear later during infection and are associated with a decline
of the immune response and with the onset of AIDS [22–27].
CXCR4 is also expressed on a large number of cancer cells and its
interaction with CXCL12 has been demonstrated to favour tumour cell
survival, proliferation and mobility leading to metastasis development
[13,28–30]. Besides CXCL12, CXCR4 also interacts with the broad-
spectrum human herpes virus 8-encoded chemokine vCCL2, which
acts as an antagonist [31]. In 2005, CXCR7 was identiﬁed as the second
CXCL12-binding chemokine receptor [32,33]. Similar to CXCR4, CXCR7
promotes cancer metastasis and its over-expression is often associated
with more aggressive tumour phenotypes and bad prognosis [34–36].
Importantly, the biology and regulation of the activity of CXCR4, CXCR7
and their common ligand CXCL12 were suggested to be interdependent
[37].
CXCR4 was shown to adopt a typical GPCR fold consisting of a
seven-transmembrane helix bundle. However, the location and shape
Table 1
Sequence and length of peptides derived from CXCR4 extracellular loops.
Name Length Position Sequence
ECL1-X4 14 97–110 DAVANWYFGNFLCK
ECL2-X4 27 176–202 NVSEADDRYICDRFYPNDLWVVVFQFQ
ECL3-X4 21 262–282 DSFILLEIIKQGCEFENTVHK
Residues in bold are solvent exposed in the CXCR4 X-ray structure.
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GPCRs and is situated closer to the receptor surface [38] suggesting a
greater implication of the N-terminus and the three extracellular loops
(ECL1, ECL2 and ECL3) in ligand binding and receptor activation
[39–41].
The tridimensional structure of chemokines consists of (1) an
elongated and ﬂexible N-terminus, (2) a cysteine motif, (3) a loop
of approximately ten residues, often referred to as the N-loop, (4) a
single-turn of 310 helix, (5) three antiparallel β-strands and (6) a
C-terminal α-helix. These secondary structures are connected by turns
known as the 30s, 40s, and 50s loops, which reﬂects the numbering of
residues in the mature protein [42,43]. The chemokine structure is
further stabilised by two disulphide bridges connecting the cysteine
residues of the N-terminus with those located on the 30s and 50s
loops [42].
On the basis of the large amount of information available for CXCL12
and CXCR4, a general two-step mechanism was proposed to describe
the interaction of chemokines with their cognate receptors [44,45].
The initial step of this model corresponds to the anchoring of the
chemokine to the receptor's N-terminus (Chemokine Recognition Site
1, CRS1) and is followed by the binding of the ﬂexible N-terminus of
the chemokine to a second site (CRS2) located in the vicinity of the
transmembrane segments (TMs) and the extracellular loops of the
receptor. In linewith thismodel, studies using sulfated peptides derived
from the N-terminal domain of CXCR4 demonstrated that peptide
corresponding to CRS1 binds the surface of CXCL12 in an extended con-
formation close to the chemokine N-loop [46,47]. Furthermore, these
studies highlighted the importance of sulfotyrosines present on
CRS1 and sulfotyrosine-binding pockets present on the chemokine.
Binding of the chemokine N-terminus to CRS2 was suggested to
induce conformational changes in the receptor and in its subsequent
activation. In agreement with this model, short peptides derived
from the ﬂexible N-terminus of CXCL12 were shown to be sufﬁcient
to speciﬁcally bind CXCR4, and displayed agonist activity [48–51].
Further analyses conducted with afﬁnity puriﬁed CXCR4 identiﬁed
several amino acids located on the CXCL12 β-sheet and 50s loop as
additional receptor interacting residues [52]. Although all these
results corroborate the two-step binding model, the exact stoichi-
ometry of the CXCR4–CXCL12 interaction as well as the receptor
determinants forming the CRS2 remain to be clariﬁed [38,46].
The critical role of CXCR4 in cancer biology and HIV-1 infection
makes this receptor and its ligands valuable targets for drug develop-
ment. To date, several small CXCR4 antagonists including AMD3100,
T140 or CTCE-9908 have been described [53–57]. Although these
molecules are very potent in blocking HIV-1 infection and metastasis
development, they are often associated with important side effects
and/or inverse action on other chemokine receptors [53,58,59].
Therefore, other inhibition strategies need to be explored. Over the
last few years, ligand neutralisation by small molecules, peptides
and antibody fragments has emerged as an interesting alternative
to the classical receptor inhibition [60–67]. However, peptidic deriv-
atives of receptor extracellular loops have never been reported
as potential chemokine neutralisers. In the context of CXCR4 and
CXCR7, targeting their common chemokine, CXCL12, would allow
the simultaneous interference with its binding to both receptors
[68]. On the other hand, the development of molecules neutralising
the HIV-1 envelope protein gp120 rather than the receptor would
confer T-cell protection against viral infection without impeding
the physiological functions of CXCR4.
In the present study, we investigated the neutralising properties of
individual peptides corresponding to the ﬁrst, second and third extra-
cellular loops (ECL1, ECL2, ECL3) of CXCR4 towards CXCL12 binding
and HIV-1 infection. Analyses with mutated and truncated peptides
provided new insights on themolecular basis of receptor–ligand recog-
nition opening new perspectives for the development of CXCR4 ligand
neutralisers.2. Materials and methods
2.1. Peptides, proteins and cells
Peptides corresponding to the extracellular loops of CXCR4
(ECL1-X4, ECL2-X4 and ECL3-X4) were designed based on
the receptor topology predicted prior to its X-ray structure
resolution [39] (Table 1). All peptides including scrambled
control peptides ECL1-X4scrbl (FNYSGAKFVNDLWA) and ECL2-
X4scrbl (DVQDPRVLDWRNDVYSFYAFQFVCINE) were purchased
from JPT and contained an amide group at the C-terminus to avoid
additional negative charges. Peptide ECL2-X4 was also purchased
biotinylated at its N-terminus and the biotin moiety was separated
from the peptide by a Ttds linker ([N1-(9-Fluorenylmethoxycarbonyl)]-
1,13-diamino-4,7,10-trioxatridecan-succinamic acid). The CXCL12 N-
terminal peptide comprised the ﬁrst 17 residues of the chemokine
(KPVSLSYRCPCRFFESH). Control peptide (SPAPERRGYSGYDVPDY)
(Ctrl) corresponded to a HCDR3 sequence binding to an antibody
directed against human inﬂuenza haemagglutinin [69]. Chemokines
CXCL12 (SDF1α), vCCL2 (vMIP-II), CCL5 (RANTES), CCL3 (MIP-Iα) and
CCL4 (MIP-Iβ) were purchased from Peprotech. Alexa Fluor 647-
labelled CXCL12 was purchased from Almac. MT-4, Cf2Th-CXCR4,
CEM.NKR, CEM.NKR-CCR5 and U87.CD4.CXCR4 cell lines were obtained
through the NIH AIDS programe from Dr. D. Richman, Dr. J. Sodroski
and Dr. A. Trkola [70–72]. Cells stably expressing CXCR7 were obtained
by transfecting U87.CD4 cells with pBABE-CXCR7 vector.
2.2. HIV-1 infection inhibition assay
Inhibition of HIV infection of MT-4 cells and peptide cytotoxicity
were measured as previously described [73,74]. MT-4 cells (6 · 104
cells/well) were incubated with or without X4 (IIIB), R5/X4 (89.6)
or R5 (Ba-L) viruses (100 TCID50) for ﬁve days in the presence of
three-fold dilutions of ECL-X4 and control peptides starting at a concen-
tration of 100 μM. Viral entry inhibition and peptide cytoxicity were
evaluated by monitoring the absorbance at 540 nm (Abs) correspond-
ing to MTT (3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium
Bromide) reduction by mitochondrial enzymes using a Multiskan As-
cent spectrophotometer (Thermo-ﬁsher). Protection (%)was calculated
using the following equation: (Abscells + virus + peptide− Abscells + virus) /
(Abscells − Abscells + virus) × 100.
Luciferase-tagged recombinant viruses harbouring the NL4.3 Env
and VSV-g pseudovirions were produced as previously described
[75–77]. U87.CD4.CXCR4 cells (10,000 cells/well) were infected in
96-well plates with Env-recombinant viruses (200 pg p24, quantiﬁed
by Perkin Elmer kit) for 48 h at 37 °C. Medium was replaced and cells
were cultured for another 48 h, after which luciferase activity was
assayed using the Promega Luciferase kit (Promega) and read on a
Polarstar Omega microplate reader (BMG labtech). All infections were
performed in triplicate. Peptide cytotoxicity was determined in unin-
fected cells using the MTT method as described above.
2.3. Binding of ﬂuorescently labelled CXCL12 to CXCR4
Alexa Fluor 647-labelled CXCL12 (100 ng/ml) was incubated for 30
min at room temperature with CXCR4 ECL-X4 peptides (50 μM) prior
addition to Cf2Th-CXCR4 cells. After 90 min incubation at 4 °C, cells
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DEAD® Fixable Dead Cell Stain, Lifetechnologies) for 30min at 4 °C and
analysed on a BD FACS Canto cytometer (BD Biosciences) using BD FACS
Diva software. Unlabelled CXCL12 chemokine (100 fold excess) was
used as positive control for Alexa Fluor 647-labelled chemokine dis-
placement, while the LIVE/DEAD stain allowed the simultaneous deter-
mination of peptide cytotoxicity.2.4. Surface plasmon resonance measurements
Surface plasmon resonance (SPR) allows sensitive real time mea-
surement of protein–protein interactions [78]. This technology is
based on the evaluation of changes in the refractive index upon binding
of an analyte to a ligand immobilised at the surface of a sensor chip.
Biotinylated ECL2-X4 peptide (1 μM)was immobilised on a streptavidin
chip (GE Healthcare) by injection at a ﬂow rate of 5 μl/min for 20min in
0.01MHEPES, pH 7.4, 0.15MNaCl, 3 mMEDTA, 0.005% (v/v) surfactant
P20 (HBS-EP) on a BIAcore 3000. Typically, a signal ranging from 1000
to 1500 RU was obtained. For all sensorgrams, signal obtained with an
irrelevant peptide (Ctrl) was subtracted from signal obtained with
ECL2-X4. Binding analyses were performed by injecting 200 nM of
CXCL12, vCCL2, CCL5, CCL3, and CCL4 for 3 min at a ﬂow rate of
30 μl/min. All binding measurements were performed in triplicate
and were presented as average ± standard deviation. Kinetic analyses
were performed by injecting various concentrations of CXCL12 and
vCCL2 (7 to 500 nM) in HBS-EP at a ﬂow rate of 30 μl/min. Association
and dissociation times of 2 min and 20 min, respectively were
recorded. Measurements were carried out in duplicate. Surface
regeneration was performed by a single injection of 10 μl of 10 mM
glycine buffer pH 1.5. The presence of mass transfer phenomena
and linked reactions was excluded by performing the control assays
as recommended by the manufacturer. Kinetic data analysis was
performed using the BIAevaluation 4.1 software. The overall dissoci-
ation constant (KD) values and on (ka) and off (kd) rates for the com-
plexes were obtained after global ﬁts of the experimental data using
a simple model for 1:1 (Langmuir) binding.2.5. cAMP assay
Primary intracellular cyclic AMP (cAMP) production upon CXCL12
binding in the presence or absence of ECL-X4 peptides was evaluated
on MT-4 cells using the TR-FRET LANCE cAMP assay (Perkin Elmer)
adapted for a 96-well plate format. MT-4 cells (2 · 104 cells/well)
were diluted in HBSS stimulation buffer (5 mM HEPES, 0.1% BSA,
0.5 mM IBMX pH 7.4) containing Alexa Fluor 647-labelled anti-cAMP
antibody. Cells were incubated with forskoline (FSK) and CXCL12 was
preincubated with ECL-X4 or control peptides for 30 min at room tem-
perature. cAMP productionwasmeasured by adding europium-labelled
streptavidin and biotin-cAMP for 1 h at room temperature. LANCE signal
was recorded at 665 nm in a TECAN Genios Pro ﬂuorimeter and com-
pared with cAMP standard curves (10−6 to 10−11 M).2.6. Intracellular calcium release
Intracellular calcium release induced by CXCL12 was measured
using indo-1-acetoxymethyl ester (Interchim) as calcium-responsive
ﬂuorescent probe. Calcium release was monitored in MT-4 cells in 20
mMHEPES buffer containing 2.5mMprobenecid and 0.1% BSA. Allmea-
surements were performed at 37 °C in a 1 ml stirred cell using wave-
lengths of 355 nm for excitation and 475 and 405 nm for emission in a
PTI QM-4 QuantaMaster ﬂuorimeter. For inhibition experiments,
CXCL12 (7.5 nM) was incubated for 10 min in the presence of CXCR4-
derived peptides (100 μM).2.7. Internalisation of CXCR4, CXCR7 and CCR5 receptors
Internalisation of CXCR4, CXCR7 and CCR5 receptors from the cell
surface was monitored by ﬂow cytometry. Phycoerythrin-conjugated
monoclonal antibodies (mAb) 12G5 (BD Pharmingen) and 4G10
(Santa Cruz Biotechnology) were used to follow CXCR4 internalisation
from the surface of MT-4 cells. Phycoerythrin-conjugated monoclonal
antibodies T21/8 (EBiosciences) and 11G8 (R&D Systems) were used
to monitor CCR5 and CXCR7 internalisation from CEM.NKR-CCR5 and
U87-CXCR7 cells, respectively.
Cells were incubated for 30 min in the presence of CXCL12 (50 nM),
CCL5 (20 nM) or vCCL2 (400 nM). For neutralisation experiments,
chemokines were pre-incubated 30 min at 37 °C with ECL-X4 and
control peptides. Internalisation was stopped after 30 min by addition
of NaN3 (0.1%) and placing cells on ice. Cells were then stained with
the adequate antibody for 30 min at 4 °C. Cell viability and potential
cytotoxic effect of peptides was monitored using the LIVE/DEAD®
Fixable Dead Cell Stain. Samples were analysed on a BD FACS Canto
cytometer (BD Biosciences) using BD FACS Diva software.
2.8. Chemotaxis
Chemotaxis assays were performed in ChemoTx 96-well cell migra-
tion systems (Neuro Probe) equipped with a 5 μm-pore polycarbonate
membrane ﬁlter as recommended by the manufacturer. Brieﬂy, migra-
tion buffer (RPMI 1640) containing CXCL12 (12 nM) and two-fold
dilutions of ECL-X4 and control peptides (3 μM to 100 μM)were loaded
in the lower chamber. Calcein-AM loaded Jurkat cells (2.5 · 105 cells)
were added to the upper chamber. Migration was allowed for 2 h and
15 min at 37 °C. Cells in upper and lower chambers were counted by
measuring ﬂuorescence (Eex 485 nm, Eem 525 nm) using a Tecan Genios
Pro ﬂuorimeter.
3. Results
3.1. Inhibition of HIV infection by ECL-X4 peptides
The ECL-X4 peptides (Table 1) were analysed for their ability to
inhibit the infection of MT-4 cells with the laboratory-adapted CXCR4-
using (X4) HIV-1 strain IIIB (Fig. 1A). Peptides ECL1-X4 and ECL2-X4
fully protected cells from virus cytopathic effect (IC50 = 24 and
31 μM, respectively) whereas peptide ECL3-X4 displayed 10% protec-
tion at a concentration of 100 μM. No inhibition was observed with
the control peptide or the scrambled ECL1-X4 and ECL2-X4 peptides
(ECL1-X4scrbl and ECL2-X4scrbl) (Fig. 1A, B and D). None of these pep-
tideswere toxic within the concentration range tested as demonstrated
in Fig. 1SD. Interestingly, peptide ECL1-X4 also protected MT-4 cells
against infectionwith dual-tropic (R5/X4) virus (89.6) aswell as against
the CCR5-using (R5) virus (Ba-L) with IC50 values of 69 μM and 76 μM,
respectively (Fig. 1B). In contrast, peptide ECL2-X4 failed to protect cells
against R5 virus and displayed a reduced protection against dual-tropic
virus (Fig. 1D).
To deﬁne the minimal length and crucial residues of ECL1-X4 and
ECL2-X4 involved, truncated and mutated peptides were analysed in
MT-4 infection assays (Fig. 1C, D and E). While progressive truncation
of the ﬁrst two N-terminal residues of ECL1-X4 (ECL1-X498–110 and
ECL1-X499–110) reduced protection (IC50 = 43 μM and 67 μM), deletion
of the C-terminal lysine (Lys110) (ECL1-X497–109) abrogated its antiviral
properties (Figs. 1C, 7A). In contrast, mutation of the cysteine at position
109 to an alanine (C109A) did not modify the antiviral potency (IC50 =
22 μM) indicating that protection is independent of peptide dimer
formation.
Truncated 18-mer ECL2-X4 analogues (ECL2-X4176–193, ECL2-
X4181–198 and ECL2-X4185–202) failed to inhibit infection of MT-4
cells by X4 virus IIIB (Figs. 1D, 7C) demonstrating the necessity of full
length ECL2-X4 peptide for viral inhibition. Alanine scanning of peptide
Fig. 1. Inhibition of HIV-1 infection by ECL-X4 peptides. Protection of MT-4 cells against HIV-1 infection by ECL-X4 peptides was evaluated by determining cell survival after 5 days of
infection in an MTT assay. Panel A: Inhibition of X4 HIV-1 (IIIB) infection by ECL-X4 peptides. Panel B: Inhibition of X4 (IIIB), R5/X4 (89.6) and R5 (Ba-L) HIV-1 infection by peptide
ECL1-X4. Panel C: Inhibition X4 HIV-1 (IIIB) infection by full-length (ECL1-X497–110), truncated (ECL1-X498–110, ECL1-X499–110, ECL1-X497–109, ECL1-X497–108, and ECL1-X498–109), mutated
(ECL1-X4C109A) and scrambled (ECL1-X4scrbl) peptides (Fig. 7A). Panel D: Inhibition of X4 (IIIB) R5/X4 (89.6) and R5 (Ba-L) HIV-1 infection by full-length (ECL2-X4176–202), truncated
(ECL2-X4176–193, ECL2-X4181–198 and ECL2-X4185–202) and scrambled (ECL2-X4scrbl) peptides (Fig. 7C). Panel E: Inhibitory properties of alanine mutated ECL2-X4 analogues. Data are pre-
sented as percentage of protection obtained at a concentration of 200 μM. All experiments were performed in triplicate and are presented as average ± standard deviation. Panel F: In-
hibition of NL4.3 recombinant virions and VSV-g pseudoparticles by ECL-X4 peptides. U87.CD4.CXCR4 cells were infected with recombinant HIV particles harbouring the CXCR4-using
envelope protein (NL4.3) and of VSV-g pseudovirions in the presence of serial 3-fold dilutions of ECL-X4, scrambled (scrbl) and control (ctrl) peptides. Viral infection was evaluated by
measuring luciferase activity in cell lysates after 4 days. Data are presented as percentage of the infection obtained in the absence of peptide. All experiments were performed in triplicate
and are presented as average ± standard deviation.
1034 A. Chevigné et al. / Biochimica et Biophysica Acta 1843 (2014) 1031–1041ECL2-X4 revealed different inhibitory behaviour of alanine analogues
and identiﬁed three clusters of residues important for efﬁcient protec-
tion (Figs. 1E, 7B). While mutations R183A (IC50 = 68 μM) or R188A
(IC50 = 50 μM) slightly affected the antiviral properties of the peptides,
mutations Y184A, I185A, C186A, D187A,N192A (IC50=176 μM), L194A
(IC50 = 83 μM), V196A and V197A (IC50 = 123 μM) resulted in less ac-
tive peptides and mutations N176A, V177A, S178A, E179A, D181A,D182A, F189A, Y190A, P191A, D193A and W195A, V198A, F199A,
Q200A and Q202A abolished HIV inhibitory properties.
ECL-X4 peptides and controls were further analysed for their ability
to interfere with viral entry using an Env recombinant virus harbouring
CXCR4-using envelope (NL4.3) and VSV-g pseudovirions. Whereas
ECL2-X4 inhibited only NL4.3 viral entry with an IC50 value of 9.6 μM,
it displayed no activity against VSV-g pseudoparticles indicating that
Fig. 2. Inhibition of CXCL12 binding to CXCR4 by ECL-X4 peptides. Panel A: Inhibition of CXCL12 binding to Cf2Th cells expressing CXCR4 by ECL1-X4, ECL2-X4, ECL3-X4 and control (Ctrl)
peptides (50 μM). Panel B: Comparison of CXCL12 inhibitory properties of ECL2-X4 and ECL-X4scrbl peptides (200 μM to 10 nM). Alexa Fluor 647-labelled CXCL12 (AF647-CXCL12)
(100 ng/ml) was pre-incubated with CXCR4 or control peptides for 30 min at RT before addition on Cf2Th–CXCR4 cells for 90 min at 4 °C. All experiments were performed in duplicate
and are presented as average ± standard deviation.
Fig. 3. Binding speciﬁcity of peptide ECL2-X4. Binding was evaluated by surface plas-
mon resonance (SPR) using a biotinylated ECL2-X4 peptide immobilised on a SA-chip.
CXCL12, vCCL2, CCL5, CCL3, and CCL4 chemokines were injected at 200 nM. Binding
intensities corresponding to SPR signals recorded at the end of the association phase are
presented as average values± standard deviation of triplicate experiments. Insets: Kinetic
analysis of thebindingof peptide ECL2-X4 to chemokines CXCL12 (upper panel) andvCCL2
(lower panel). Measurements were performed with two-fold dilutions of chemokine
starting at 500 nM. Kinetic rate constants (ka and kd) for both complexes were ﬁtted
globally according to a Langmuir 1:1 model using BIAevaluation 4.1 software. The
ﬁtting results were ka = 4.01 ± 0.05 × 105 M−1 s−1, kd = 8.84 ± 0.07 × 103 s−1,
KD = 22.1 ± 0.5 nM for ECL2-X4/CXCL12 and ka = 1.86 ± 0.02 × 105 M−1 s−1, kd =
5.05 ± 0.04 × 103 s−1, KD = 27.1 ± 0.5 nM for ECL2-X4/vCCL2, respectively.
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viral entry (Fig. 2). In contrast, at a concentration of 100 μM ECL1-X4
peptide partially interfered with both NL4.3 and VSV-g mediated
entry. At concentrations of 33 to 11 μM, the peptide favoured viral
entry, while at lower concentrations it had no effect. These observations
suggest that part of the antiviral activity observedwith ECL1-X4 peptide
on MT-4 cells can be related to non-speciﬁc effects.
3.2. Chemokine binding and neutralisation by ECL-X4 peptides
ECL-X4 peptides were also analysed for their ability to inhibit the
binding of ﬂuorescently labelled CXCL12 to CXCR4. This labelled chemo-
kine speciﬁcally bound to Cf2Th cells overexpressing CXCR4 and not to
the parental Cf2Th cells (Fig. 2SD). Only peptide ECL2-X4 inhibited
binding of ﬂuorescently labelled CXCL12 to CXCR4 in a dose-dependent
manner (Fig. 2) (IC50 = 2 ± 1 μM). No inhibition was observed with
ECL1-X4, ECL3-X4, scrambled ECL2-X4 (ECL2-X4scrbl) and Ctrl peptides
(Fig. 2). Surface plasmon resonance experiments demonstrated a strong
and speciﬁc binding of ECL2-X4 to CXCR4-related chemokines in solu-
tion (CXCL12 KD = 22 ± 0.5 nM, and vCCL2 KD = 27 ± 0.5 nM). This
data indicated that the reduced binding of ﬂuorescent CXCL12 in the
presence of ECL2-X4 was related to chemokine neutralisation and not
receptor–peptide interactions (Fig. 3).
3.3. Inhibition of CXCL12-induced CXCR4/CXCR7 signalling and
internalisation by ECL-X4 peptides
The effect of ECL-X4 peptides on the CXCR4G-protein signallingwas
further investigated (Fig. 4A and B). In agreementwith the binding data,
in cAMP assay, only peptide ECL2-X4 inhibited the CXCL12-induced
CXCR4 activation (IC50 = 35 ± 0.5 μM) whereas ECL1-X4, ECL3-X4
and control peptide had no effect (Fig. 4A). In the absence of CXCL12,
none of the ECL-X4 peptides acted as a CXCR4 agonist (data not
shown). Similar results were obtained with CXCL12-induced calcium
release measurement (Fig. 4B). ECL1-X4, ECL3-X4 and control peptide
did not exert any effectwhereas ECL2-X4 peptide abolished the calcium
response induced by CXCL12 with an IC50 of 5.7 μM (Fig. 4B, inset). The
inhibitory properties of ECL2-X4 peptide were conﬁrmed in a receptor
internalisation assay using the 4G10 mAb directed against the CXCR4
N-terminus (Fig. 4C). Using this antibody avoided interference betweenmAbs recognising the CXCR4 ECLs. As previously observed, only peptide
ECL2-X4 inhibited CXCL12-induced CXCR4 internalisation (IC50= 19±
2 μM) (Figs. 4C and 5). The ability of peptide ECL2-X4 to inhibit the
CXCL12-induced migration of leukaemia-derived T cells was also mon-
itored using a Transwell system. Peptide ECL2-X4 abolished chemotaxis
of Jurkat cells at concentrations higher than 50 μMwhile only partial or
no inhibition was observed with peptides ECL3-X4 and ECL1-X4,
respectively (Fig. 4D). Finally, the inhibitory properties of peptide
ECL2-X4 towards CXCL12-induced CXCR7 internalisation were eval-
uated (Fig. 5). Peptide ECL2-X4 inhibited CXCR7 internalisation albeit
with less potency than was observed for CXCR4 (IC50 = 100 ± 24 μM
vs. IC50 = 19 ± 2 μM).
Fig. 4. Inhibition of theCXCL12-CXCR4 signalling pathways by ECL-X4 peptides. Panel A:Modulation of cAMPproduction bypeptides ECL1-X4, ECL2-X4, ECL3-X4 and control.Modiﬁcation
of the forskolin-induced cAMP production was monitored using the TR-FRET-based LANCE assay. CXCL12 (30 nM) was pre-incubated with peptides (100 μM) for 30 min at 37 °C before
addition on MT-4 cells. Inset: Dose-dependent inhibition of CXCL12 by peptide ECL2-X4 (10 nM to 200 μM). Panel B: Inhibition of CXCL12-induced calcium release by ECL-X4 peptides.
Antagonist properties were monitored in the presence of CXCL12 (7.5 nM) by measuring maximum calcium response using Indo-1 ﬂuorescence. Inset: Dose-dependent inhibition of
CXCL12-induced calcium release by peptide ECL2-X4 (100 μM to 10 nM). Panel C: Inhibition of CXCL12-induced CXCR4 internalisation in MT-4 cells. CXCL12 (50 nM) was pre-
incubated with ECL-X4 peptides (100 μM) for 30 min at 37 °C before addition on MT-4 cells for 30 min at 37 °C. CXCR4 surface expression was monitored by ﬂow cytometry using the
4G10 antibody. Panel D: Inhibition of CXCL12-induced migration of leukaemia-derived T-cells by ECL-X4 peptides. All experiments were performed in duplicate and are presented as
average ± standard deviation.
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The ability of peptide ECL2-X4 to neutralise vCCL2 was also eval-
uated (Fig. 7C). This chemokine binds to CXCR4 as well as to other
CXC and CC chemokine receptors including CCR5. As vCCL2 displays
an inherent antagonist activity, its binding to chemokine receptors
was monitored in competition experiments. To avoid any interference
between ECL-X4 peptides and the competing mAbs, the binding of
vCCL2 was monitored on CCR5-expressing cells using the anti-CCR5
T21/8 mAb. At concentration of 400 nM vCCL2 abolished the binding
of the anti-CCR5 antibody to the receptor, while in the presence of
peptide ECL2-X4, this binding was fully restored, demonstrating
that peptide ECL2-X4 also neutralised vCCL2. This interaction was
concentration-dependent with a potency equivalent to that observed
for CXCL12 (IC50 = 29 ± 6 μM vs. IC50 = 19 ± 2 μM). Peptide ECL2-
X4 had no effect on CCL5 binding to CCR5 conﬁrming its speciﬁcity.3.5. Inhibition of full-length and CXCL12 N-terminus-derived peptide by
truncated and mutated ECL2-X4 analogues
To unravel the structural basis of CXCL12 and vCCL2 neutralisation
by ECL2-X4, partially overlapping truncated 18-mer peptides covering
the full-length sequence of ECL2-X4 (176–193, 181–198 and 185–202)
were analysed in a CXCR4 internalisation assay (Figs. 5, 6 and 7C). Trun-
cation of the C-terminal residues (ECL2-X4176–193) abrogated the inhib-
itory properties of the peptide, while peptides ECL2-X4181–198 and ECL2-
X4185–202 displayed only 30% of the full-length ECL2-X4 activity at the
highest concentration tested (300 μM) (Fig. 5). Similar proﬁles were
observed for vCCL2, although the analogue ECL2-X4181–198 displayed
stronger inhibition potency (Fig. 6). To assess the importance of individ-
ual amino acids for the neutralising properties of ECL2-X4 towards
CXCL12, the IC50 values of alanine mutants were determined (Fig. 8A).
Only the P191A mutant almost completely lost its capacity to inhibit
Fig. 5. Inhibition of the binding of CXCL12 to CXCR4 and CXCR7 by ECL2-X4-derived pep-
tides. Neutralisation properties towards CXCL12were evaluated in receptor internalisation
assays. CXCL12 (50 nM) was pre-incubated with different concentrations (10 nM to
300 μM) of ECL2-X4 and truncated analogues for 30 min at 37 °C prior addition on cells
for 30 min at 37 °C. The surface expression of CXCR4 was monitored using the 4G10 anti-
body (−CXCR4) while CXCR7 expression was detected with the 11G8 antibody
(−CXCR7). Full-length ECL2-X4 peptide covered positions 176 to 202. Truncated ECL2-
X4peptides (ECL2-X4176–193, ECL2-X4181–198 and ECL2-X4185–202) arepartially overlapping
18-mers covering the entire ECL2 sequence (Fig. 7C). Data represent themean± standard
deviation of duplicate experiments.
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replacement of residues Asp181 (D181A, IC50 = 38 ± 3 μM), Asp182
(D182A, IC50 = 63 ± 7 μM), Asp187 (D187A, IC50 = 46 ± 5 μM),
Asp193 (D193A, IC50 = 75 ± 9 μM) and Cys186 (C186A, IC50 = 91 ±
8 μM) as well as the hydrophobic residues Leu194 (L194A, IC50 = 38 ±
8 μM), Trp195 (W195A, IC50 = 50 ± 5 μM), Val196 (V196A, IC50 =
44 ± 11 μM), Val197 (V197A, IC50 = 47 ± 6 μM) and Phe201 (F201A,
IC50 = 50 ± 15 μM) located at the C-terminus of peptide ECL2-X4
resulted in more than two-fold reduction in CXCL12-neutralising prop-
erty. In contrast, the removal of positively charged residues in mutants
R183A (IC50 = 15 ± 3 μM) and R188A (IC50 = 14 ± 3 μM) slightly
favoured chemokine binding.
To further pinpoint the CXCL12 region involved in the interaction
with ECL2-X4, neutralisation of the short agonist peptide derived
from the N-terminus of CXCL12 (residues 1–17) was evaluated inFig. 6. Inhibition of vCCL2 binding to CCR5 by ECL2-X4-derived peptides. Neutralisation
properties towards vCCL2 were evaluated in internalisation assay (−vCCL2). vCCL2
(400 nM) was pre-incubated with different concentrations of ECL2-X4 peptides (10 nM
to 300 μM) for 30 min at 37 °C before addition on CCR5-expressing cells for 30 min at
37 °C. Control experiment was performed using CCL5 (20 nM) (−CCL5). CCR5 surface
expression was detected with the T21/8 antibody. Full-length ECL2-X4 peptide covers
positions 176 to 202. Truncated ECL2-X4 peptides (ECL2-X4176–193, ECL2-X4181–198 and
ECL2-X4185–202) are partially overlapping 18-mers covering the entire ECL2 sequence
(Fig. 7C). Data represent the mean ± standard deviation of duplicate experiments.internalisation assay as this peptide alone was shown to induce recep-
tor internalisation with an EC50 of 50 μM (Fig. 8B). As observed for
full-length chemokine, peptide ECL2-X4 inhibited over 70% of CXCR4
internalisation induced by this agonist peptide indicating that ECL2-X4
neutralises CXCL12 predominantly by binding to its ﬂexible N-terminal
extremity.
4. Discussion
4.1. Different properties of ECL1-X4 and ECL2-X4 against HIV infection
Among the ECL-X4 peptides, ECL1-X4 and ECL2-X4 displayed potent
antiviral activity against replicative viruses without inducing any
toxicity effects. These peptides were soluble in the concentration
range tested excepted peptide ECL2-X4scrbl which was partially
insoluble in the culture media at a concentration of 100 μM. In
infection inhibition assay using MTT readout ECL1-X4 protected
cells from infection with X4, R5/X4 but also R5 virus strains. Peptides
covering positions 99 to 110 were required to achieve antiviral
properties. The ability of peptide ECL1-X4 to inhibit viruses of
different tropisms may be partially explained by the high sequence
similarity of ECL1 in CXCR4 and CCR5. Indeed, ECL1 of CXCR4
(DAVANWYFGNFLCK) and CCR5 (YAAAQWDFGNTMCQ) show 50%
of sequence identity and signiﬁcant homology at non-conserved
positions (Fig. 7A). Antiviral properties have previously been reported
for a CCR5 derived ECL1 peptide (ECL1-R5) using fusion assay [79].
This peptide inhibited the cell-to-cell fusion entry of R5 and R5/X4
envelopes with potency in the micromolar range but was inactive
against X4 virus envelope. These ﬁndings suggested an important
role for the non-conserved residues in tropism determination. In agree-
ment with this hypothesis, Asp97 of ECL1 of CXCR4 was shown to be
critical for efﬁcient infection by CXCR4-using viruses [80].
However, it must be noted that in entry assays with VSV-g
pseudotypes and HIV (NL4.3) recombinant particles, ECL1-X4 blocked
50% of the total infection at 100 μM and increased cell infection by
two to four-fold at 11 and 33 μM. This suggests that the peptide may
interact non-speciﬁcally with other viral surface determinants or
interfere with other steps of the virus cell cycle. Recently, the antiviral
activities of a synthetic mimic of CXCR4 extracellular surface covering
ECL1–ECL2–ECL3 or cyclic peptides corresponding to ECL1 and ECL2
were described [81,82]. The former mimic of the extracellular surface
showed inhibition in the low micromolar range (IC50 = 10 μM) and
was active only against X4-virus. This observation may result from theFig. 7. Sequence alignment of full-length and truncated ECL1-X4 and ECL2-X4 peptides.
Panel A: Sequences of full-length (positions 97 to 110) and truncated ECL1-X4 peptides.
The N- and C-terminal extremities of peptide ECL1-X4 are important (DA) or critical (K)
for HIV-1 inhibition and are coloured in red. Residues identical in ECL1 of CXCR4 and
CCR5 are underlined. Panel B: Full-length ECL2-X4 peptide (positions 176 to 202). Resi-
dues within ECL2-X4 critical for HIV-1 inhibition (upper line) or important for CXCL12
neutralisation (IC50 values twice as high as the wild-type peptide) (lower line) are
coloured in red and blue respectively. Panel C: Sequence alignment of truncated overlap-
ping 18-mer ECL2-X4 peptides. Underlined asparagines (N) correspond to putative
N-glycosylation sites (NXS/T).
Fig. 8.Mutational scanning of peptide ECL2-X4 and its inhibitory properties towards CXCL12 and the agonist peptide derived from CXCL12 N-terminus. Panel A: Inhibition of CXCL12-
induced CXCR4 internalisation by ECL2-X4 mutants monitored by ﬂow cytometry. IC50 values are compared to that recorded with wild-type (WT) peptide ECL2-X4 (IC50 = 19 ±
2 μM) (red dotted line). Panel B: Neutralisation of the agonist peptide derived from CXCL12 N-terminus (residues 1–17) by peptide ECL2-X4. CXCL12 N-terminus peptide (50 μM) was
pre-incubated with various ECL2-X4 concentrations (10 μM to 300 μM) and neutralisation was monitored as the decrease of CXCL12 N-terminus-induced CXCR4 internalisation. Exper-
iments were performed in duplicate and are presented as average ± standard deviation.
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themimic towards X4 viruses. Cyclic ECL1 and ECL2 peptides displayed
IC50 values of 35 μM and 32 μM, very similar to what we observed with
individual linear peptides using the MTT readout. However, the activity
of ECL1-derived peptides was observed indirectly by measuring cell
viability and should also be further investigated using entry assays
and Env of different viruses.
Peptide ECL2-X4 inhibited the CXCR4-using virus strain IIIB with
potency similar to ECL1-X4 (i.e. low micromolar range). Truncation
and mutational analyses showed that full-length peptide is required
for protection and the majority of the residues, with the notable excep-
tion of Arg183, Arg188, Val197 and Leu194, were important for efﬁcient
inhibition (Fig. 1E). The critical residues were present as three clusters
covering positions 176 to 182, 189 to 195 and 198 to 202, with theFig. 9. Spatial arrangement of CXCR4 extracellular domains and positioning of ECL2 residues in
extracellular surface (PDB 3ODU). Disulphide bridges (red dots) of the extracellular parts of CX
green)potentially involved indifferent steps of ligand binding. Panel B:Overall CXCR4 receptor a
displayed IC50 values two fold higher than the wild-type peptide ECL2-X4 are represented as
towards the inner face of the receptor. Panel C: Structure of CXCR4 dimer and location of CXCL1
are coloured green and blue. Receptor dimerisation mainly involves the extracellular surface oﬁrst two including mainly solvent-exposed residues involved in the
β-hairpin structure (Figs. 7B and 9B). These results are in linewith stud-
ies conducted on cells expressingmutated CXCR4, which demonstrated
the importance of aromatic and negatively charged residues of ECL2 for
HIV-1 entry [39–41,83]. In contrast to ECL1-X4, ECL2-X4 did not protect
cells against infection by CCR5-using viruses, which could be explained
by the poor sequence identity (10%) observed between the correspond-
ing regions of CXCR4 and CCR5. It has been demonstrated that peptides
derived from the second extracellular loop of CCR5 are also potent
HIV-1 inhibitors [79,84]. These studies, however reported conﬂicting
results regarding the antiviral effect of ECL2-R5 against dual-tropic
and CXCR4 viruses, which may be attributed to the differences in
entry assays used (cell–cell fusion vs. single round infectivity
assay). It is worth noting that a recent NMR study conducted usingvolved in interactions with CXCL12 and its N-terminus. Panel A: Top-down view of CXCR4
CR4 divide the receptor into two distinct domains (Nterm-ECL3 in blue and ECL1–ECL2 in
nd localisation of ECL2. Residues located in ECL2/top of TM5,which in internalisation assay
sticks and are coloured orange. Side chains of residues D181, D182, D187 and D193 point
2 N-terminus-binding sites (ECL2 and the top of TM5 coloured orange). CXCR4monomers
f TM5 and TM6 and brings two CXCL12 N-terminus-binding sites in close vicinity.
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identiﬁed several gp120-interacting residues (underlined, 181-
HFPYSQYQFW-190) corresponding to the second cluster pointed
out in the present study (189-FYPNDLW-195) [84].
In CXCR4, the top of TM3 (end of ECL1) and ECL2 are linked by a
disulphide bond. A second disulphide bond is present between the
N-terminus of the receptor and the top of TM7 (end of ECL3) (Fig. 8A).
Based on the positioning of these disulphide bridges and the overall
receptor topology, the extracellular surface can be divided into two
structural domains (Nterm–ECL3 and ECL1–ECL2) potentially involved
in discrete steps of ligand recognition (Fig. 9A). As in the case of
chemokines, the binding of gp120 to the co-receptors has been pro-
posed to occur as a two-step process with the N-terminus forming the
ﬁrst gp120-recognition site and the extracellular loops supporting the
second binding step [85]. The recognition of the CXCR4 N-terminus
seems however less important than the N-terminus of CCR5 for CCR5-
mediated entry [86–88]. Furthermore, our results demonstrate that
peptide ECL1-X4 and ECL3-X4 are less effective than ECL2-X4 in
preventing HIV-1 entry, reinforcing the view that the latter is the key
gp120-binding determinant of CXCR4.
4.2. ECL2-X4 neutralises CXCL12 by binding to its ﬂexible N-terminus —
molecular basis for CRS2 interaction
Based on our data, ECL2 ismost likely to be themajor determinant of
the CXCR4 CRS2. Indeed, only peptides derived from this loopwere able
to speciﬁcally bind CXCL12 and inhibit its interactions with CXCR4
thereby preventing receptor activation. The binding of CXCL12 to
CXCR4 is generally described as a two-step mechanism [44]. While the
receptor N-terminus is commonly accepted as the major determinant
of the initial chemokine recognition (CRS1), the residues constituting
CRS2 involved in the subsequent receptor-activating interaction with
the chemokine N-terminus are not precisely deﬁned. In silico predic-
tions pointed out residues located in ECL2, ECL3 as well as the TM5
and TM6 regions [41,44,89]. While full-length ECL2-X4 peptide was
needed for efﬁcient chemokine neutralisation, mutational analysis
highlighted the crucial role of Pro191. Furthermore, Cys186, the four
aspartate residues scattered along the peptide (Asp181, Asp182,
Asp187 and Asp193) as well as the LWVV cluster and Phe200 located
at the C-terminal part of ECL2 were important for neutralisation
(Figs. 7B, 8A and 9B). In the CXCR4 crystal structure, all four aspartates
are solvent-exposed and ideally positioned on the loop to interact
with ligands (Fig. 9B). Pro191 was crucial for both CXCL12 and HIV-1
neutralisation, most probably by reducing the ﬂexibility of this region
and introducing a kink at the C-terminus of ECL2 upstream the
LWVVVFQFQ sequence (annotated as the top of TM5 in the X-ray
structure). This kink may be necessary for correct positioning of
the N- and C-terminal parts of the peptide for optimal ligand binding.
Based on this structural arrangement, a plausible mechanism for the
initial interactions of CXCL12 at CRS2 would rely on stabilising con-
tacts of the four aspartates with the core and the N-terminus (Arg8
and Arg12) of the chemokine, ensuring the correct orientation of
its ﬂexible N-terminus for receptor-activating insertion in the trans-
membrane cavity close to the top of TM5 (Fig. 3SD). This insertion
would result in conformational changes in the TM5 and TM6 region,
allowing the formation of new interactions between the N-terminal
lysine of CXCL12 and Asp262 or Glu288 located at the inner segment
of TM6 and TM7, respectively [44]. In accordance with the proposed
mechanism, the agonist activity of the small peptide derived from
CXCL12 N-terminus was inhibited by peptide ECL2-X4. The ﬂexible
N-terminus of the chemokine has also been shown to represent a
potential scaffold for development of drugs targeting CXCR4 [51].
Interestingly, dimeric peptides derived from CXCL12 and vCCL2
N-termini showed ten times stronger activity in inhibiting HIV-1
infection or CXCL12 binding than their monomeric counterparts
[48–51]. The molecular basis for this increase in potency is not entirelyunderstood. Nevertheless, it is noteworthy that in the crystal structure,
CXCR4 is present in a dimeric form (Fig. 9C). The dimerisation, which
takes place at the extracellular side of the TM5–TM6 region, brings the
two CXCL12 N-terminus-binding sites closer together in a symmetric
manner which could therefore account for more favourable bivalent
interactions of the dimeric peptideswith a dimeric form of the receptor.
To date, the exact stoichiometry of CXCL12–CXCR4 interactions
remains to be clariﬁed [38]. As observed for CXCR4, CXCL12 can also
form dimers and monomeric or dimeric forms of the chemokine were
shown to have different effects on signalling and cellular responses
[46,90]. Our data indicate that peptide ECL2-X4 binds to CXCL12 by
formingmultiple contacts with an important contribution of the hydro-
phobic and negatively charged residues, reminiscent of the interactions
described for CXCR4 N-terminus peptides (CRS1) and CXCL12 [46].
Indeed, peptides corresponding to CRS1 bound the chemokine in an
extended conformation and occupied the cleft delimited by N-loop
and the β-sheet leaving the ﬂexible N-terminus of the chemokine free
for an interaction with ECL2 (CRS2). It is therefore conceivable that
the interaction at CRS1 positions the chemokine, induces conformation
changes or creates larger interaction interface facilitating the subse-
quent binding of the chemokine at CRS2. However, the binding of
CRS1-derived peptides to CXCL12 has also been demonstrated to induce
its dimerisation and the formation of a symmetric 2/2 complex inwhich
the two receptor N-terminus-binding sites are located at opposing faces
of the dimer [46]. Therefore, it is also plausible that the CRS1 and CRS2-
derived peptides (N-term and ECL2) recognise equivalent sites on each
monomer providing structural basis for the binding of dimeric CXCL12.4.3. Therapeutic potential of ECL-X4-derived peptides
During the last two decades, peptides derived from the N-loop of
CCL5, the N-termini of CXCL12 [49] and vCCL2 [50], the variable loop
of gp120 (V3 loop) and the extracellular surface (N-term and ECLs) of
CCR5 [79] were proposed as potential sources of antiviral molecules.
In this study, peptide ECL2-X4 displayed antiviral properties towards
CXCR4-using viruses and interacted strongly and speciﬁcally with
CXCL12, blocking its interactions with both CXCR4 and CXCR7. Consid-
ering the increasing number of studies reporting the implication of
these receptors in the spread and survival of tumour cells, neutralising
their common ligand may be a highly relevant therapeutic strategy
[35,91–93]. Peptide ECL2-X4 was however less potent in inhibiting the
binding of CXCL12 to CXCR7 than to CXCR4, which may be in part
explained by the ten times higher afﬁnity of CXCL12 towards CXCR7
(Fig. 4) [32,33]. In contrast to peptides derived from the N-terminus of
chemokine receptors, peptides derived from the extracellular loops do
not require tyrosine sulfation to be fully active [67]. The N-terminus of
CXCR4 bears three sulfotyrosines at positions 7, 12 and 21, which
were previously shown to be critical for CXCL12 binding [46,94]. We
have previously observed that an unsulfated peptide derived from the
N-terminus of CXCR4 (residues 1–40) displayed no CXCL12 or HIV-1
inhibition properties in the different assays presented above. This
post-translational modiﬁcation is usually difﬁcult to introduce at
multiple sites of long synthetic peptides due to the lability of sulfate
group often resulting in a heterogeneous mixture of sulfated peptide
species. This observation emphasises the therapeutical potential of
peptides derived from the receptor extracellular loops. However,
their potency, afﬁnity and stability (low micromolar range) as well
as the pharmacokinetic properties remain to be largely improved
through stabilisation in a protein scaffold or by incorporating non-
natural residues such as D-amino acids or chemical derivatives.
Recent modiﬁcations of CCL5-derived peptides at hot spots demon-
strated that such rational design allowed improving the overall pep-
tide potency by more than 100 times to reach the nanomolar range
[95,96]. Therefore, the mutational analyses conducted in this study
provide valuable positional information for such further improvements.
1040 A. Chevigné et al. / Biochimica et Biophysica Acta 1843 (2014) 1031–1041In the near future, additional work will be needed to better under-
stand the structural determinants of CRS1 and CRS2 in CXCR4 and
CXCR7, as well as to elucidate the ligand–receptor stoichiometry and
to determine if the chemokine neutralising properties observed with
ECL2-derived peptides can be extended to other CXC receptors.
4.4. Conclusions
Linear peptides derived fromCXCR4 extracellular loops are structur-
al and functional mimics of the complete receptor surface and some
display neutralising properties towards CXCL12 binding and HIV-1
infection.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.01.017.
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